Table 4.

Joint effects of serum sRAGE with CML-AGE, insulin and smoking in association with colorectal cancer^a

sRAGE	CML-AGEb	Case (N)	Control (N)	RRc (95% CI)
≥ median	< median	125	122	1.0 (ref)
≥ median	≥ median	82	120	0.88 (0.55–1.40)
< median	< median	127	121	1.33 (0.85–2.08)
< median	≥ median	149	122	1.73 (1.10–2.71)
sRAGE	Insulin
≥ median	< median	110	130	1.0 (ref)
≥ median	≥ median	97	112	1.34 (0.81–2.21)
< median	< median	158	108	2.20 (1.40–3.45)
< median	≥ median	118	135	1.62 (0.99–2.64)
sRAGE	Year of smoking
≥ median	< 35	79	128	1.0 (ref)
≥ median	≥ 35	128	114	1.59 (0.88–2.87)
< median	< 35	137	134	2.09 (1.31–3.32)
< median	≥ 35	139	109	2.32 (1.26–4.26)

^aP value for the joint effect was 0.01 for sRAGE and CML-AGE, 0.03 for sRAGE and insulin, 0.07 for sRAGE and years of smoking.

^bCML-AGE was adjusted for sRAGE using the residual method.

^cRR was adjusted for age, years of smoking, BMI, and serum glucose for the joint effect with CML-AGE; RR was adjusted for serum CML-AGE in addition for the interaction by insulin and years of smoking.